DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 06 · Volume 49 · November 2016 DOI: 10.1055/s-006-32812 Special Issue Child/Adolescent Psychopharmacology

Editorial

  • 217
    Juckel, G.:

    Editorial to Child and Adolescence Psychopharmacology

    • Review

  • 219
    Kölch, M.; Plener, P. L.:

    Pharmacotherapy in Psychiatric Disorders of Children: Current Evidence and Trends

    • Commentary

  • 226
    Vitiello, B.:

    Pediatric Psychopharmacology

  • 227
    Holtmann, M.; Schimmelmann, B. G.:

    From Psychopharmacological Evidence to Clinical Practice: Unmet Needs in Child & Adolescent Psychiatry – Reflections on Kölch & Plener

    • Review

  • 229
    Lambert, M.; Niehaus, V.; Correll, C.:

    Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder

    • Commentary

  • 244
    Birmaher, B.:

    The Challenge of Defining Prodromal Symptoms of Schizophrenia and Bipolar Disorders

  • 246
    Schimmelmann, B. G.; Holtmann, M.:

    Early Intervention in Psychosis and Bipolar Disorder in Children and Adolescents – Reflections on Lambert, Niehaus and Correll

    • Original Paper

  • 248
    Blázquez, A.; Gassó, P.; Mas, S.; Plana, M. T.; Lafuente, A.; Lázaro, L.:

    One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms

  • 254
    Trinczek, E.; Heinzel-Gutenbrunner, M.; Haberhausen, M.; Bachmann, C. J.:

    Time to Initiation of Clozapine Treatment in Children and Adolescents with Early-Onset Schizophrenia

    • Letter to the Editor

  • 260
    Naudet, F.:

    Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?

  • 261
    Soyka, M.; Friede, M.; Schnitker, J.:

    Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis – Comment to Naudet

  • 262
    Langgartner, S.; Strube, W.; Oviedo, T.; Hansbauer, M.; Karch, S.; Wirth, S.; Falkai, P.; Hasan, A.:

    Treatment-resistant Schizophrenia and Global Cortical Atrophy in a Patient with Turner Syndrome